 |
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N’-[3,5-bis(trifluoromethyl)phenyl]urea |
|---|---|
| Trade Name | |
| Orphan Indication | Sickle cell anemia |
| USA Market Approval | USA |
| USA Designation Date | 2002-05-13 00:00:00 |
| Sponsor | NeuroSearch A/S;93 Pederstrupvej, DK-2750 Ballerup; |
Related Access Program